


Ask a doctor about a prescription for LORMETAZEPAM VIR 1 mg TABLETS
Package Leaflet: Information for the User
Lormetazepam Vir 1 mg Tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack:
Lormetazepam Vir contains lormetazepam, which belongs to a group of medicines called benzodiazepines. It is indicated for the short-term treatment of insomnia.
Benzodiazepines are only indicated for the treatment of a severe disorder, which limits the patient's activity or puts them in a situation of significant stress.
Do not take Lormetazepam Vir
In case of acute intoxication with alcohol, sleeping pills, pain relievers or psychotropic medications (neuroleptics, antidepressants, lithium salts).
Warnings and precautions
Consult your doctor or pharmacist before starting to take lormetazepam:
If any of the following cases apply to you, inform your doctor. Your doctor will take this into account during treatment with lormetazepam.
Be aware that you may experience the following reactions:
Tolerance
After continued use for several weeks, a certain degree of loss of efficacy with respect to the hypnotic effects may be detected.
Amnesia
Benzodiazepines, including lormetazepam, may induce amnesia (memory alteration). This fact occurs more frequently after several hours of administration of the medicine, so to reduce the associated risk, patients should ensure that they sleep uninterruptedly for 7-8 hours after taking the tablet.
Dependence and abuse
Treatment with benzodiazepines may lead to the development of physical and psychological dependence. This risk increases with the dose and duration, but dependence can also occur during short-term treatment with the therapeutic dose range.
To prevent this risk as much as possible, the following precautions should be taken into account:
Rebound insomnia and anxiety
When administration is stopped, the symptoms that led to the taking of the medication may reappear, as well as mood changes, anxiety, insomnia, restlessness, among others, so your doctor will indicate precisely how to gradually decrease the dose.
Lormetazepam should not be stopped abruptly and a gradual dose reduction process should be followed.
Psychiatric and paradoxical reactions
In treatment with benzodiazepines, including lormetazepam, pre-existing depressions may reappear or worsen. Additionally, they may unmask the suicidal tendencies of depressive patients, which should be monitored in these patients.
The medication should be discontinued if these reactions appear.
Using Lormetazepam Vir with other medicines
Tell your doctor or pharmacist if you are using or have recently used or may need to use any other medicine.
The simultaneous use of lormetazepam with opioids (analgesics, substitution therapy medications, and some cough medicines) increases the risk of drowsiness, breathing difficulties (respiratory depression), coma, and can be life-threatening. Due to this, concomitant administration should only be considered when no alternative treatments are possible.
However, if your doctor prescribes lormetazepam along with opioids, the dosage and duration of concomitant treatment should be limited by your doctor.
Please inform your doctor of all opioids you are taking and carefully follow the dosage recommendations indicated by your doctor. It may be helpful to inform friends or family members to be aware of the signs and symptoms indicated above. Contact your doctor if you experience such symptoms.
Alcohol increases the sedative effect of this medication, so it is recommended to avoid alcohol consumption.
Certain medications may interact with lormetazepam and make you feel more drowsy than expected. These are medications called central nervous system depressants, including those used to treat mental illnesses such as antipsychotics (neuroleptics), hypnotics, anxiolytics/sedatives, antidepressants; those used to relieve strong pain (narcotic analgesics); those used to treat seizures/epileptic attacks (antiepileptics); anesthetic medications; barbituric medications; and medications used to treat allergies (sedating antihistamines).
The concomitant administration of lormetazepam with other medications such as theophylline or aminophylline, beta-blockers, cardiac glycosides, oral contraceptives, and some antibiotics may alter the effect of lormetazepam by prolonging or decreasing its activity. The effect of muscle relaxants may be enhanced.
Taking Lormetazepam Vir with food, drink, and alcohol
Avoid alcohol consumption during treatment with lormetazepam as it increases the sedative effect of this medication.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
The use of benzodiazepines, including lormetazepam, appears to be related to a possible increased risk of congenital malformations in the first trimester of pregnancy. Benzodiazepines and their metabolites have been detected passing through the placenta.
If, for strict medical necessity, the product is administered during a late phase of pregnancy or at high doses during labor, it is foreseeable that effects on the newborn may appear, such as hypoactivity, hypothermia, hypotonia (low muscle tone), apnea (breathing difficulties), moderate respiratory depression, feeding problems, and metabolic response imbalance to cold stress.
Children born to mothers who take benzodiazepines chronically during several weeks of pregnancy or during the last period of pregnancy may develop physical dependence and trigger withdrawal syndrome in the postnatal period.
Breastfeeding
Lormetazepam should not be used during breastfeeding, as benzodiazepines, including lormetazepam, are excreted in breast milk. Cases of sedation and inability to suckle have been detected in newborns whose mothers were under treatment with benzodiazepines. These newborns should be monitored to detect any of the mentioned pharmacological effects (including sedation and irritability).
Use in children and adolescents:
Benzodiazepines are not indicated in children or adolescents, except for premedication for diagnostic or surgical procedures (anesthesiology, intensive care). In these cases, a single dose of 1 mg is recommended.
Use in elderly and debilitated patients
Elderly and debilitated patients should receive a lower dose since they are more susceptible to the effects of the medication. Follow your doctor's instructions carefully.
Due to the muscle relaxant effect, there is a risk of falls and consequently fractures in elderly patients, especially in patients who get up during the night.
Use in patients with respiratory failure
Lormetazepam is contraindicated in patients with severe respiratory failure.
Use in patients with liver failure
Lormetazepam should be used with caution in patients with severe liver failure and/or encephalopathy.
Grief or loss
In cases of loss or grief, psychological adjustment may be inhibited by benzodiazepines.
Driving and using machines
Lormetazepam is a medication that causes sleepiness. Do not drive or use machines if you feel drowsy or if you notice that your attention and reaction capacity are reduced. Pay special attention at the start of treatment or if the dose is increased.
Lormetazepam Vir contains lactose
If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.
Lormetazepam Vir contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially “sodium-free”.
Follow exactly the administration instructions of this medicine indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
Your doctor will indicate the duration of your treatment with lormetazepam. The duration of the treatment should be as short as possible.
Treatment should be started with the lowest doses and the maximum dose should not be exceeded
Adults:
The recommended dose is 1 tablet (1 mg of lormetazepam) daily, 15 to 30 minutes before bedtime, administered orally.
The usual dose may be increased at the doctor's discretion in case of severe or persistent insomnia that does not respond to the usual regimen, up to 2 tablets daily, which means a maximum of 2 mg of lormetazepam.
Use in children and adolescentss
Lormetazepam is not indicated for the treatment of insomnia in children and adolescents.
Elderly patients, debilitated patients, or patients with cerebrovascular disorders (arteriosclerosis), mild or moderate respiratory failure, and/or renal and/or hepatic impairment.
The dose should be reduced to 0.5 mg of lormetazepam per day. To achieve this dose, other presentations of lormetazepam are available.
For severe respiratory failure, see section 2.
Do not interrupt treatment abruptly. Your doctor will indicate the precise way to gradually decrease the dose, as when administration is stopped, the symptoms that led to the taking of the medication may reappear.
The tablet can be divided into equal doses.
If you take more Lormetazepam Vir than you should
The symptoms of overdose with benzodiazepines are generally manifested by different degrees of central nervous system depression, which can range from drowsiness to coma.
In moderate cases, symptoms include drowsiness, confusion, lethargy, and dysarthria (speech disorders). In more serious cases, ataxia (incoordination of voluntary movement), paradoxical reactions, central nervous system depression, hypotonia, hypotension, respiratory depression (breathing difficulties), cardiac depression, coma, and death may appear.
Treatment of overdose: the clinical management of overdose of any medication should always take into account the possibility that the patient has ingested multiple products.
After a benzodiazepine overdose, vomiting should be induced (before one hour) if the patient is conscious. Inducing vomiting is not recommended if there is a risk of aspiration. If the patient is unconscious, gastric lavage should be performed with preservation of the airway. If gastric emptying does not provide any advantage, activated charcoal should be administered to reduce absorption.
Special attention should be paid to respiratory and cardiovascular functions if the patient requires admission to an intensive care unit for monitoring.
Use of antidote in case of overdose: in hospitalized patients, flumazenil (a benzodiazepine antagonist) can be used as a complementary method in the treatment of overdose, but never as a substitute for the method described above. In patients who chronically take benzodiazepines or in cases of overdose with tricyclic antidepressants, special care should be taken when administering flumazenil, as this association of medications can increase the risk of seizures.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Lormetazepam Vir
Do not take a double dose to make up for forgotten doses.
If you stop taking Lormetazepam Vir
Do not stop treatment with lormetazepam until your doctor tells you to.
If you stop taking lormetazepam, especially if it is abruptly, mood changes, anxiety, insomnia, and restlessness, among others, may appear.
Your doctor will explain how to gradually decrease the dose until the end of your treatment.
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
According to frequency, they are defined as:
Very common(may affect more than 1 in 10 people): Headache.
Common(may affect up to 1 in 10 people):
Anxiety, changes in libido, and bradypnea. Dizziness, sedation, drowsiness, attention disorders, amnesia, dysarthria (slurred speech), dysgeusia. Tachycardia. Vomiting, nausea, upper abdominal pain, constipation, dry mouth. Pruritus. Urination disorders. Asthenia, hyperhidrosis, malaise.
Very rare(may affect up to 1 in 10,000 people):
Hypersensitivity. Syndrome of inappropriate antidiuretic hormone secretion (SIADH), hyponatremia. Visual problems (including double vision and blurred vision). Hypotension (decreased blood pressure). Respiratory failure, apnea, worsening of sleep apnea, worsening of chronic obstructive pulmonary disease (COPD). Increased liver transaminases and increased alkaline phosphatase in blood. Allergic dermatitis.
Frequency not known (cannot be estimated from the available data):
Angioedema. Completed suicide, attempted suicide (due to the unmasking of pre-existing depression), acute psychosis, hallucination, dependence, drug abuse, depression (unmasking of pre-existing depression), deception, rebound insomnia syndrome, agitation, aggression, irritability, restlessness, anger, nightmares, state of confusion, delirium, abnormal behavior, emotional disorder, psychomotor retardation. Low level of consciousness, ataxia, convulsion, tremor, extrapyramidal disorders. Nystagmus (involuntary eye movement). Urticaria, rash. Muscle weakness, muscle cramps. Fatigue, hypothermia, paradoxical reactions.
Due to the muscle relaxant effect, there is a risk of falls and consequently fractures in elderly patients.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects that are not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Store below 30°C. Store in the original packaging to protect it from light.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date is the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to your pharmacist. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Lormetazepam Vir 1 mg tablets
Appearance of the product and packaging content
Lormetazepam Vir 1 mg is presented in packs containing 30 tablets. The tablets are white, round, beveled, engraved with a "1" on one of their faces and scored on the other. The tablets can be divided into equal doses.
Marketing authorization holder and manufacturer
INDUSTRIA QUÍMICA Y FARMACÉUTICA VIR, S.A.
C/Laguna 66-68-70. Polígono Industrial Urtinsa II
28923 – Alcorcón (Madrid)
Spain
Date of the last revision of this leaflet: May 2023
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
The average price of LORMETAZEPAM VIR 1 mg TABLETS in November, 2025 is around 2.01 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for LORMETAZEPAM VIR 1 mg TABLETS – subject to medical assessment and local rules.